Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Preclinical data support novel approaches for the treatment of Usher Syndrome 2A and retinitis pigmentosa 4 Preclinical data support novel approaches for the treatment of Usher Syndrome 2A and retinit
Best Biotech Stocks & ETFs for mRNA, Gene Editing
05:17pm, Thursday, 29'th Apr 2021
Here is what you should know about investing in these life changing technologies.
Editas Medicine to Host Conference Call Discussing First Quarter 2021 Results and Corporate Update
07:01am, Wednesday, 28'th Apr 2021
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednes
Editas (EDIT) to Report Q1 Earnings: Whats in the Cards?
09:01am, Tuesday, 27'th Apr 2021
On Editas' (EDIT) first-quarter earnings call, investor focus is expected to be on the company's progress with the development of its lead pipeline candidate - EDIT-101.
CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today
03:51pm, Friday, 16'th Apr 2021
A "sell" rating is one thing, but a price target barely half of the Thursday close? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.
Nasdaq Stays Flat as Workhorse Drives Higher, Editas Sinks
03:31pm, Friday, 16'th Apr 2021
Investors are trying to figure out which stocks have the best prospects.
EDIT Stock: Over 15% Decrease Intraday Explanation
03:14pm, Friday, 16'th Apr 2021
The stock price of Editas Medicine Inc (NASDAQ: EDIT) has decreased by over 15% during intraday trading. This is why it happened.
Why Editas Medicine Stock Is Getting Crushed Today
02:39pm, Friday, 16'th Apr 2021
Investors are running for the hills following this analyst take on the biotech's prospects.
Goldman Sachs Just Put Editas Stock on Sale — Buy the Dip
02:05pm, Friday, 16'th Apr 2021
Goldman says Editas' clinical data may underwhelm. We don't agree.
Spring Cleaning for Investors
03:14pm, Thursday, 08'th Apr 2021
Start this year's spring cleaning by asking yourself the right questions.
An End to This Rare Syndrome Could Be an Opportunity for Investors
10:58am, Wednesday, 07'th Apr 2021
A rare genetic disease that causes combined blindness and deafness may have a novel treatment in line after positive phase 1/2 trial results last month.
ARK Genomic Revolution Multi-Sector ETF: Poised For Continued Underperformance
07:27am, Friday, 02'nd Apr 2021
ARK Genomic Revolution Multi-Sector ETF: Poised For Continued Underperformance
3 Stocks More Than 25% Off Their 2021 Highs That Could Still Make You Rich
05:52am, Monday, 29'th Mar 2021
All three of these stocks appear to be great comeback candidates.
Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today
01:26pm, Wednesday, 10'th Mar 2021
Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players. The post Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and ED
Editas, Intellia: After Big Sell Off, Is it Time To Buy Gene Editing Stocks?
09:30am, Monday, 08'th Mar 2021
Our indicative theme of Gene Editing stocks is down by about 24% year-to-date, compared to the S&P 500 which has remained almost flat over the same period. The recent sell-off comes on the back of ris
